Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UNC13A precursor messenger RNA (UNC13A pre-mRNA)
- Target
- UNC13A pre-mRNA
- Molecular classification
- Precursor messenger RNA (pre-mRNA), Non-coding RNA (while unspliced/transiently non-coding), Synaptic protein transcript (as context for its protein product), Other (gene-specific RNA, not a protein or enzyme)
01
Overview
UNC13A pre-mRNA is the precursor transcript transcribed from the UNC13A gene, essential for forming the mature UNC13A mRNA. Correct splicing of this RNA is necessary for producing the functional UNC13A protein, which is vital for synaptic vesicle priming, neurotransmitter release, and neuronal communication. Defects in UNC13A pre-mRNA splicing, most notably the inclusion of a disease-associated cryptic exon (especially following loss of nuclear TDP-43), result in reduced UNC13A protein and are genetically linked to increased risk for ALS and FTD. Therapeutic strategies targeting UNC13A pre-mRNA (such as splice-modulating ASOs) aim to restore normal splicing and protein levels, offering hope for disease modification in neurodegeneration[1][2][3][4][5][6][7].
- Other names
- UNC13A RNAUNC13A transcriptUnc13a gene transcriptMunc13-1 transcript
02
Mechanism of action
ASOs modulate RNA splicing to prevent cryptic exon inclusion, restore correct UNC13A mRNA, and normalize protein expression
03
Biological functions
Regulation of synaptic vesicle priming (via eventual protein product)Control of neurotransmitter release and synaptogenesisModulation of axon growth and branchingRNA processing and splicing (in context of disease mechanism)
04
Disease associations
Neurodegenerative disease (notably ALS and FTD)Genetic risk factor for ALS and FTD (via SNP-dependent mis-splicing)Potential role in Alzheimer's disease (pathological mis-splicing observed)
05
Safety considerations
Risk of off-target RNA modulation affecting other splicing eventsNeurotoxicity associated with altered synapse function if mis-targetedUncertain effects on synaptic activity with overcorrection or broad modulation
06
Interacting drugs
Antisense oligonucleotides (ASOs) directed at correcting UNC13A mis-splicing
07
Biomarkers
Presence of cryptic exon in UNC13A mRNADisease-associated SNPs in UNC13A intronic regionReduction in full-length UNC13A protein
Beyond the preview
Go deeper on UNC13A precursor messenger RNA (UNC13A pre-mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UNC13A precursor messenger RNA (UNC13A pre-mRNA).